Standout Papers

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-lab... 2016 2026 2019 2022 422
  1. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial (2016)
    William D. Tap, Robin L. Jones et al. The Lancet

Immediate Impact

4 by Nobel laureates 1 from Science/Nature 51 standout
Sub-graph 1 of 23

Citing Papers

The hallmarks of cancer immune evasion
2024 Standout
Ultralight crystalline hybrid composite material for highly efficient sequestration of radioiodine
2024 Standout
2 intermediate papers

Works of Ashwin Shahir being referenced

Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
2023
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
2016 Standout

Author Peers

Author Last Decade Papers Cites
Ashwin Shahir 465 393 169 26 651
Douglas Adkins 383 353 119 18 638
Amy Qin 465 453 129 12 681
Alejandro Yovine 420 416 116 24 718
Maria Marples 350 500 103 30 700
Geraldine Goss 482 439 139 24 791
U. Matulonis 246 341 79 32 584
Daniela Katz 352 314 156 29 601
I. Ray-Coquard 416 336 92 28 676
Rümeysa Çiftçi 240 376 129 43 754
Josefina Cruz 504 369 167 30 623

All Works

Loading papers...

Rankless by CCL
2026